These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 11410888)
21. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. Maruyama I; Sadato N; Waki A; Tsuchida T; Yoshida M; Fujibayashi Y; Ishii Y; Kubota T; Yonekura Y J Nucl Med; 1999 Jul; 40(7):1085-90. PubMed ID: 10405124 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535 [TBL] [Abstract][Full Text] [Related]
23. Comparison of MRI and PET as Potential Surrogate Endpoints for Treatment Response After Stereotactic Radiosurgery in Patients With Brain Metastasis. Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ AJR Am J Roentgenol; 2018 Dec; 211(6):1332-1341. PubMed ID: 30240297 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Gómez-Río M; Rodríguez-Fernández A; Ramos-Font C; López-Ramírez E; Llamas-Elvira JM Eur J Nucl Med Mol Imaging; 2008 May; 35(5):966-75. PubMed ID: 18172642 [TBL] [Abstract][Full Text] [Related]
25. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492 [TBL] [Abstract][Full Text] [Related]
27. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging]. Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892 [TBL] [Abstract][Full Text] [Related]
28. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. Levivier M; Massager N; Wikler D; Lorenzoni J; Ruiz S; Devriendt D; David P; Desmedt F; Simon S; Van Houtte P; Brotchi J; Goldman S J Nucl Med; 2004 Jul; 45(7):1146-54. PubMed ID: 15235060 [TBL] [Abstract][Full Text] [Related]
29. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. Xiangsong Z; Weian C J Neurooncol; 2007 May; 82(3):305-11. PubMed ID: 17120157 [TBL] [Abstract][Full Text] [Related]
30. Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to gamma knife radiosurgery. Lee JK; Liu RS; Shiang HR; Pan DH J Comput Assist Tomogr; 2003; 27(4):525-9. PubMed ID: 12886136 [TBL] [Abstract][Full Text] [Related]
32. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Yamamoto T; Nishizawa S; Maruyama I; Yoshida M; Tsuchida T; Waki A; Fujibayashi Y; Kubota T; Yonekura Y; Itoh H Ann Nucl Med; 2001 Apr; 15(2):103-9. PubMed ID: 11448067 [TBL] [Abstract][Full Text] [Related]
33. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531 [TBL] [Abstract][Full Text] [Related]
34. Clinical applications of PET in brain tumors. Chen W J Nucl Med; 2007 Sep; 48(9):1468-81. PubMed ID: 17704239 [TBL] [Abstract][Full Text] [Related]
35. Metabolic Evolution of Brain Metastasis After Stereotactic Radiosurgery: Mismatch Between F-DOPA and FDG PET. Cicone F; Carideo L; Villani V; Scaringi C; Bozzao A; Scopinaro F; Minniti G Clin Nucl Med; 2020 Jul; 45(7):557-558. PubMed ID: 32371619 [TBL] [Abstract][Full Text] [Related]
36. [Validation of MRI and 18F-FDG-PET coregistration in patients with primary brain tumors]. Ortega-López N; Mendoza-Vásquez RG; Adame-Ocampo G; Alexanderson-Rosas E; Cayetano-Alcaraz AA; Angel-Celis M Gac Med Mex; 2007; 143(4):309-16. PubMed ID: 17969839 [TBL] [Abstract][Full Text] [Related]
38. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862 [TBL] [Abstract][Full Text] [Related]
39. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962 [TBL] [Abstract][Full Text] [Related]
40. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. Prat R; Galeano I; Lucas A; Martínez JC; Martín M; Amador R; Reynés G J Clin Neurosci; 2010 Jan; 17(1):50-3. PubMed ID: 19959364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]